AzurRx BioPharma, Inc. AZRX
3.45 +3.45
Day range unavailable
52-week range unavailable
News
globenewswire.com AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22 Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22
pennystocks.com 3 Penny Stocks That Top Investors Buying Right Now Which penny stocks are you watching in September 2021? Here's three for some watchlist inspiration The post 3 Penny Stocks That Top Investors Buying Right Now appeared first on Penny Stocks to Buy,…
benzinga.com 46 Biggest Movers From Yesterday Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share.
zacks.com AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.
benzinga.com 36 Stocks Moving In Tuesday's Mid-Day Session Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results.
globenewswire.com AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the…
benzinga.com 72 Biggest Movers From Yesterday Gainers
seekingalpha.com AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
benzinga.com AzurRx BioPharma Announces Reverse Merger With First Wave Bio AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments. First Wave Bio is a clinical-stage…
globenewswire.com AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI”
globenewswire.com AzurRx BioPharma Announces Reverse Stock Split Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021 Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021
globenewswire.com AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract Phase 2 placebo-controlled clinical trial to confirm…
globenewswire.com AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections Review of Interim Safety Data Concluded with Favorable Recommendation to Continue RESERVOIR Trial as Planned
globenewswire.com AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis Proposed Phase 1b/2a clinical trial designed to determine safety and potential efficacy of oral and topical FW-420 Proposed Phase 1b/2a clinical trial designed to determine safety and potential…
globenewswire.com AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference BOCA RATON, Fla., Sept. 07, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies…
pennystocks.com 3 Penny Stocks That Top Investors Are Buying Right Now Top traders are watching these penny stocks right now, here's why The post 3 Penny Stocks That Top Investors Are Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Information |…
zacks.com AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints AzurRx (AZRX) is developing lead pipeline candidate as monotherapy and in combination regimen as potential treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis.
investorplace.com AZRX Stock: The Huge Trial News Lifting Little-Known AzurRX BioPharma Today Today, AZRX stock is making headlines after the company showed some impressive results from a clinical trial of a cystic fibrosis treatment. The post AZRX Stock: The Huge Trial News Lifting…
pulse2.com AzurRx BioPharma Shares Increase Over 40% Pre-Market: Why It Happened The shares of AzurRx BioPharma, Inc. (NASDAQ: AZRX) increased by over 40% pre-market. This is why it happened.
globenewswire.com AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI) BOCA RATON, Fla., Aug. 18, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies…
benzinga.com Stocks That Hit 52-Week Lows On Tuesday Tuesday morning, 282 companies set new 52-week lows.
globenewswire.com AzurRx BioPharma Announces WHO Publication of “Adrulipase Alfa” as International Nonproprietary Name for MS1819 BOCA RATON, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies…
globenewswire.com AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections BOCA RATON, Fla., Aug. 10, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant…
pulse2.com AZRX Stock Price Increases Over 30% Pre-Market: Details You Should Know The stock price of AzurRx BioPharma Inc (NASDAQ: AZRX) increased by over 30% pre-market. These are some details you should know.- benzinga.com Stocks That Hit 52-Week Lows On Monday Stocks That Hit 52-Week Lows On Monday Monday morning, 285 companies reached new 52-week lows.
benzinga.com 81 Biggest Movers From Yesterday Gainers- benzinga.com Stocks That Hit 52-Week Lows On Thursday
benzinga.com Stocks That Hit 52-Week Lows On Wednesday - benzinga.com Stocks That Fell Through 52-Week Lows Wednesday
- benzinga.com Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018
benzinga.com Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018 - benzinga.com Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018
- benzinga.com 36 Stocks Moving In Wednesday's Mid-Day Session
- benzinga.com Stocks Which Set New 52-Week Low Yesterday, October 11th
- benzinga.com 41 Stocks Moving In Tuesday's Mid-Day Session
benzinga.com 51 Biggest Movers From Yesterday - benzinga.com 42 Stocks Moving In Monday's Mid-Day Session
- benzinga.com Stocks Which Set New 52-Week Low Yesterday, July 30th
- benzinga.com 36 Biggest Movers From Friday
- benzinga.com 30 Stocks Moving In Friday's Mid-Day Session
benzinga.com 35 Biggest Movers From Yesterday